AIP
LUCD icon

Ameritas Investment Partners’s Lucid Diagnostics LUCD Stock Holding History

Ameritas Investment Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.56K Hold
7,067
– – ﹤0.01% 3051
2026
Q1 		$8.13K Hold
7,067
– – ﹤0.01% 2904
2025
Q4 		$7.7K Hold
7,067
– – ﹤0.01% 2964
2025
Q3 		$7.14K Hold
7,067
– – ﹤0.01% 3013
2025
Q2 		$8.13K Buy
+7,067
New +$9.13K ﹤0.01% 3034
2022
Q2 		– Sell
-390
Closed -$1K – 3163
2022
Q1 		$1K Hold
390
– – ﹤0.01% 3064
2021
Q4 		$2K Buy
+390
New +$3.17K ﹤0.01% 3094

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ameritas Investment Partners's LUCD Position: Q2 2026 in Review

Ameritas Investment Partners held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 7,067 shares worth $7.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

Ameritas Investment Partners first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. The position peaked at $8.13K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Ameritas Investment Partners held 7,067 shares of Lucid Diagnostics worth $7.56K as of Q2 2026.
  • Ameritas Investment Partners left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #3051 holding.
  • Ameritas Investment Partners first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
  • Ameritas Investment Partners's Lucid Diagnostics position peaked at $8.13K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.